Answer
Campto (irinotecan) should be used during pregnancy only if clearly necessary, given limited human data and animal embryotoxicity and teratogenicity; pregnancy must be excluded before starting treatment in women of childbearing potential and avoided if either partner receives irinotecan.
Sources for this answer
- Campto 20mg/ml concentrate for solution for infusion (40mg presentation)Pfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 27Document updated
Sources checked